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Antibiotic therapy in patients currently
treated with corticosteroids is common in
chronic respiratory diseases when exacer-
bation symptoms attributable to infection
appear. Among them, obstructive diseases
such as asthma and chronic obstructive
pulmonary disease (COPD) are major health
issues affecting hundreds of million people
worldwide that are frequently treated with
inhaled corticosteroids. Systemic corticos-
teroids are also used for idiopathic pulmo-
nary fibrosis, a less prevalent chronic
respiratory disease. In this issue of EMBO
Molecular Medicine, Earl et al (2015) report
a potentially baleful relationship between
steroid and antibiotic treatment in chronic
respiratory diseases, affecting colonization
persistence and antibiotic tolerance for
Haemophilus influenzae, one of the leading
potentially pathogenic microorganisms
(PPMs) of the respiratory system.
See also: CS Earl et al (August 2015)
A sthma and COPD are chronic inflam-matory diseases that manifest asepisodic or chronic dyspnoea, and
have common characteristics in a proportion
of patients, currently identified as asthma–
COPD overlap syndrome (ACOS) (Bujarski
et al, 2015). Both asthma and COPD patients
with an ACOS clinical pattern show in most
cases eosinophilic inflammation of their
bronchial tree and respond well to cortico-
steroid treatment administered as a long-
term inhaled therapy in most patients (Kew
et al, 2014). Eosinophilic inflammation is in
fact the most common host-response pattern
in asthma (Haldar et al, 2008) and justifies
the generalized use of corticosteroids to treat
this disease. This treatment is also often
used in COPD, is related to the appearance
of pneumonia (Festic & Scanlon, 2015) and
is currently restricted to patients with
frequent exacerbations.
Bronchial colonization by PPMs is
common in COPD (Rosell et al, 2005) as well
as in severe asthma with partial reversibility
and neutrophilic inflammation (Wenzel,
2012). In these diseases, chronic bacterial
colonization is foremost composed of several
bacterial species, including Haemophilus
influenzae. Interaction between long-term
corticosteroid treatment and bronchial colo-
nizers has not been accurately assessed in
patients, mainly due to the generalized use
of this therapy in severe disease, making it
difficult to compare with referent non-treated
patient populations. As an emerging prob-
lem, patients with neutrophilic asthma
poorly respond to steroid treatment and
suffer from recurrent exacerbations, most of
them due to bacterial infection (Biegelman
et al, 2014). Under this scenario, elevated
doses of steroids are often applied, which
may cause severe side effects.
Antibiotic therapy failure correlates with
bacterial biofilms. There is a high priority of
awareness and many reports on bacterial
biofilm-associated diseases exist describing
their mechanisms on antibiotic tolerance. In
the United States, an estimated 1.7 million
hospital-acquired infections were reported
annually and many of them are based on
biofilm-related bacteria (Monina Klevens,
2007). The spectrum of biofilm-associated
diseases is wide, and bacteria living in biofilm
consortium show profound changes in lifestyle
and metabolism that often preclude adequate
targeting by antibiotic administration.
Treatment of COPD recurrent exacerba-
tions, and of its ACOS phenotype, also
combines steroids and antibiotics. This
pharmacologic regimen is related to current
therapy for asthma and includes bronchodi-
lators, corticosteroids and antibiotics. In this
clinical setting, the spectrum of PPMs associ-
ated with chronic colonization and exacer-
bations includes bacteria species such as
H. influenzae, the microorganism addressed
by Earl and colleagues who focused on the
response of H. influenzae strains to the pres-
ence or absence of glucocorticosteroids.
Earl et al (2015) show that steroids
promote an increased persistence of H. influ-
enzae treated with beclomethasone, with
enhanced bacterial load in the lungs of
treated mice. To characterize the steroid
response of bacteria, the impact of beclo-
methasone was determined at the transcrip-
tome level of H. influenzae. Subsequently,
bacterial genes were identified as significantly
deregulated due to the presence of glucocorti-
costeroids. Among such genes were factors
involved in virulence-associated functions
such as iron uptake, biofilm formation,
stress response, antimicrobial resistance and
adherence. These bacterial genes were
further identified as being expressed in
glucocorticosteroid-treated lungs colonized
by H. influenzae, indicating their responsive-
ness in the mouse colonization model. To
prove whether steroid-responsive bacterial
gene expression is also detectable in a clini-
cal set-up, a cohort of patients was moni-
tored and RNA tested for H. influenzae
specific gene expression in sputum samples.
The results show that all H. influenzae-colo-
nized patients were positive for the cortico-
steroid-responsive bacterial genes.
To identify signal transduction compo-
nents, which carry the glucocorticosteroid
signal into the bacterial cell, a reporter strain
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was mutagenized. A panel of mutants was
screened for loss of steroid response, yield-
ing in a small subset of isolates mutated for
genes involved in stress response and factors
implicated in the adaptation of H. influenzae
to lung infection. A most interesting gene
candidate is a RpoE homolog, and RpoE-
controlled genes are known to counteract
extracytoplasmic stress in many bacteria.
Ample knowledge exists for the RpoE regu-
lon (Barchinger & Ades, 2013). For example,
the system generates a response to physical,
chemical or enzymatic caused stress condi-
tions that target the outer membrane or peri-
plasm. Earl et al (2015) characterized RpoE-
dependent regulated genes in H. influenzae
and show that glucocorticosteroids modify
such response patterns, interfering with the
RpoE network regulation. The study further
shows that glucocorticosteroids impact
biofilm formation and antibiotic tolerance:
when glucocorticosteroid was added, biofilm
development showed significant structural
alterations (Fig 1). Such modification corre-
lated with increased tolerance to azithromy-
cin, a commonly administered antibiotic in
patients with asthma. Earl et al (2015) also
tested a rpoE knockout mutant that indicated
a similar trend to wild-type bacteria biofilm
when exposed to glucocorticosteroids. Thus,
evidence was provided whereby corticoste-
roids mediate phenotypes related to the
RpoE signalling pathway. Finally, they
convincingly show that rpoE knockout
mutant behaves similarly for azithromycin
tolerance, as compared with wild-type strain
colonization in lung infection treated with
glucocorticosteroids. Collectively, such data
suggest that in the presence of glucocortico-
steroids, the persistence of H. influenzae in
the lung is increased and enhanced antibi-
otic tolerance is promoted (Fig 1).
Abnormal local responses to the chronic
presence of H. influenzae in the bronchial
tree of chronic respiratory patients may be
then partly mediated through inhaled corti-
costeroid treatment and, more importantly,
current inhaled and systemic treatments
may influence the pattern of changes in
colonizing strains, determining, at least in
part, the appearance of acute symptoms.
The findings in the study of Earl et al
(2015) may have significant clinical impli-
cations, considering the insights that recent
research on bronchial microbiota has
pointed out in chronic respiratory diseases,
emphasizing the differential patterns of
bronchial colonizers, related to severity
and symptoms (Hilty et al, 2010; Millares
et al, 2014).
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Figure 1. Steroid therapy and bacterial biofilm.
In the presence of steroids, biofilm conversion is taking place, which correlates with increased colonization
persistence and antimicrobial resistance.
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